retatrutide clinical trials phase 3 Lilly's triple agonist achieves 16.8% weight loss in trial Doctor Reveals The MOST POWERFUL

The enhanced feeling of satiety associated with GLP-1s can also improve binge eating behaviors

Smooth, safe injections start with good technique and proper medication care

Pivoting back to the obesity space, a year-long Phase 2 study comparing semaglutide daily to 0.6 mg of liraglutide daily and placebo demonstrated the superiority of semaglutide over liraglutide in all doses above 0.2 mg (NCT02453711)

Skip it at your own risk

New study: 1 in 5 GLP-1 users develop nutritional deficiencies This week, I'm unpacking a brand new study by Butsch et al

Despite these promising early findings, both studies have limitations, including the single-center design, modest sample size, short follow-up in SKIP, reliance on self-reported outcomes, and lack of multicenter validation